PROSPECT OF USING BIOTECHNOLOGIES FOR CORRECTION OF LIVER FAILURE (Review of literature)
Abstract
The review presents and discusses modern conceptions about causes of development, existing ways of prevention and correction of liver failure. Unsatisfactory effectiveness of traditional infusion and medicinal therapy, as well as low availability of extracorporal detoxification and liver transplantation methods generates a need for search of brand new patogeneticaly substantiated methods of treatment of liver failure. The data about pathogenesis of liver failure and about sanogenesis and regeneration processes are presented. Hepatocite growth factor plays leading role in that processes, most important effects of present cytokine are considered. Next part of the article describes principles, mechanism of action and results of experimental use of cell therapy method. This method has shown effectiveness in animal models and it is perspective for further improvement, but not allowed for clinical use. That's why authors consider that the most perspective solution is creation of new drug, containing regulatory peptides of liver.
About the Authors
A. I. Iskra
Scientific Center of Reconstructive and Restorative Surgery SB RAMS
Russian Federation
Russian Federation
S. A. Lepekhova
Scientific Center of Reconstructive and Restorative Surgery SB RAMS; Irkutsk Scientific Center SB RAMS; Irkutsk State Medical University
Russian Federation
Russian Federation
References
1. Александрова И.В. Экстракорпоральная гемокоррекция в комплексном лечении печеночной недостаточности: дис.. д-ра мед. наук. - М., 2009 - 251 с.
2. Гундорова Л.В. Новое в лечении хронического простатита [Электронный ресурс]. - Режим доступа: http://www.nedug.ru/library/простатит/Новое-лечении-хронического-простатита.
3. Ефанов М.Г., Кубышкин В.А., Вишневский В.А., Чжао А.В. и др. Пересадка печени от живого донора взрослому реципиенту: состояние проблемы // Анналы хирургической гепатологии. - 2006. - Т. 11, № 1. - С. 89-96
4. Кутепов Д.Е. Оптимизация лечения печеночной недостаточности на основе молекулярной адсорбирующей рециркулирующей системы: дис.. канд. мед. наук. - М., 2005 - 113 с.
5. Кутепов Д.Е., Семенов В.Н., Денисов А.Ю., Пасечник И.Н. Использование экстракорпоральных методов лечения в терапии печёночной недостаточности // Вестник интенсивной терапии. - 2004. - № 2. -С. 65-68
6. Лепехова С.А. Саногенез печёночной недостаточности под влиянием ксенотрансплантации клеток печени и селезёнки: автореф. дис.. д-ра биол. наук. -Иркутск, 2010 - 47 с.
7. Лепехова С.А., Апарцин К.А., Зарицкая Л.В., Постовая О.Н. и др. Влияние ксенотрансплантации культуры клеток печени на изменения неспецифической резистентности организма при остром токсическом повреждении печени // Сибирский медицинский журнал (г. Иркутск). - 2009. - T. 90, № 7. - C. 101-104
8. Лепехова С.А., Гольдберг О.А., Апарцин К.А., Прокопьев М.В. Дифференцированный подход к клеточной коррекции острой печёночной недостаточности при остром токсическом повреждении. Морфологическое обоснование выбора способа лечения // Бюл. ВСНЦ СО РАМН. - 2013. - № 2 (90), Ч. 1. - C. 128-192.
9. Лечение простатита: Витапрост [Электронный ресурс] / РМЖ (Русский медицинский журнал). - Режим доступа: http://www.rmj.ru/articles_1180.htm.
10. Никулин А.В. Заместительное лечение острой печеночной недостаточности методом альбуминового диализа: дис.. канд. мед. наук. - М., 2010. - 111 с.
11. Савустьяненко А.В. Церебролизин: полный спектр нейропротекторной активности [Электронный ресурс] // Международный неврологический журнал. - 2010. - № 3. - Режим доступа: www.mif-ua.com/archive/article/12207.
12. Соловьева Л.А. Простатиты: диагностика, лечение [Электронный ресурс] / Медицинский портал о здоровье Eurolab. - Режим доступа: http://www. eurolab.ua/encyclopedia/565/44989.
13. Студеникин В.М., Пак Л.А., Балканская С.В., Шелковский В.И. и др. Пептидные биорегуляторы и их применение: от неонатологии до геронто логии [Электронный ресурс] // Лечащий врач. -2010. - № 6. - Режим доступа: www.lvrach.ru/2010/06/14354644/
14. Цыпин А.Б. Спленопид - новый перспективный иммуномодулятор // Венеролог. - 2006. - № 5. -С. 34-36
15. Ang C.S., Sun M.Y., Huitzil-Melendez D.F., Chou J.F. et al. c-MET and HGF mRNA expression in hepatocellular carcinoma: correlation with clinicopathological features and survival // Anticancer Res. - 2013. - N 33 (8) -P. 3241-3245
16. Bendinelli P., Matteucci E., Dogliotti G., Massimilliano M.C. et al. Molecular basis of antiinflammatory action of platelet rich plasma on human chondrocytes: mechanisms of NF-κB inhibition via HGF // J. Cell. Phys. -2010. - N 225 (3). - P. 757-766.
17. Bravo L.C., Gregorio V.G., Shafi F., Block H.L. et al. Etiology, incidence and outcomes of acute hepatic failure in 0-18 year old Filipino children // Southeast Asian J. Trop. Med. Public Health. - 2012. - Vol. 43, N 3. -P. 764-772.
18. Chen Y.F., Tseng C.Y., Wang H.W., Kuo H.C. et al. Rapid generation of mature hepatocyte-like cells from human induced pluripotent stem cells by an efficient three-step protocol // Hepatology. - 2012. - N 55 (4). -P. 1193-1203.
19. Coudriet G.M., He J., Trucco M. Hepatocyte growth factor modulates interleukin-6 production in bone marrow derived macrophages: implications for inflammatory mediated diseases [Электронный ресурс] // PLoS One. - 2010. - N 5 (11). - Режим доступа: www. plosone.org/article/info%3Adoi%2F10.1371%2Fjournal. pone.0015384.
20. Fausto N., Laird A.D., Webber E.M. Liver regeneration. 2. Role of growth factors and cytokines in hepatic regeneration // FASEB J. - 1995. - N 9 (15). - P. 1527-1536.
21. Gadzhiev D.N., Tagiev É.G., Guseĭnaliev A.G., Gadzhiev N.D. The cytokine profile in the patients with acute calculous cholecystitis and correction of its disorders [Электронный ресурс] // Klin. Khir. - 2013. -N 4. - Режим доступа: www.ncbi.nlm.nih.gov/ pubmed/23888711.
22. Gazdhar A., Susuri N., Hostettler K., Gugger M. et al. HGF expressing stem cells in usual interstitial pneumonia originate from the bone marrow and are antifibrotic [Электронный ресурс] // PLoS One. - 2013. -N 8 (6). - Режим доступа: www.plosone.org/arti-cle/info%3Adoi%2F10.1371%2Fjournal.pone.0065453.
23. Gong R. Multi-target anti-inflammatory action of hepatocyte growth factor // Curr. Opin. Investig. Drugs. - 2008. - N 9 (11). - P. 1163-1170.
24. Gong R., Rifai A., Ge Y., Shan C. et al. Hepatocyte growth factor suppress proinflammatory NFκB activation through GSK3β inactivation in renal tubular epithelium cells // J. Biol. Chem. - 2008. - Vol. 283, N 12. - P. 7401-7410.
25. Hagman Z., Haflidadottir B.S., Ansari M., Persson M. et al. The tumour suppressor miR-34c targets MET in prostate cancer cells // Br. J. Cancer. - 2013. -N 109 (5). - P. 1271-1278.
26. Harshman L.C., Choueiri T.K. Targeting the hepatocyte growth factor/c-Met signaling pathway in renal cell carcinoma // Cancer J. - 2013. - N 19 (4). - P. 316-323.
27. Harun N., Costa P., Christophi C. Tumor growth stimulation following partial hepatectomy in mice is associated with increased upregulation of c-Met // Clin. Exp. Metastasis. - 2014. - N 1. - P. 1-14
28. Ishii T., Sato M., Sudo K., Suzuki M. et al. Hepatocyte Growth Factor stimulates liver regeneration and elevates blood protein level in normal and partially hepatectomized rats // J. Biochem. - 1995. - Vol. 117, N 5. - P. 1105-1112.
29. Ishikawa T., Factor V.M., Marquardt J.U., Raggi C. et al. Hepatocyte Growth Factor (HGF)/c-Met signaling is required for stem cell mediated liver regeneration // Hepatology. - 2012. - N 5. - P. 1215-1226.
30. Kasahara M., Umeshita K., Inomata Y., Uemoto S. Long-term outcomes of pediatric living donor liver transplantation in Japan: an analysis of more than 2200 cases listed in the Registry of the Japanese Liver Transplantation Society // Am. J. Transplant. - 2013. - N 13 (7). -P. 1830-1839.
31. Link T.W., Arifin D.R., Long C.M., Walczak P. et al. Use of magnetocapsules for in vivo visualization and enhanced survival of xenogeneic HepG2 Cell transplants // Cell Med. - 2012. - N 4 (2). - P. 77-84.
32. Mai G., Nguyen T.H., Morel P., Mei J. et al. Treatment of fulminant liver failure by transplantation of microencapsulated primary or immortalized xenogeneic hepatocytes // Xenotransplantation - 2005. - N 12 (6). -P. 457-464.
33. Mei J., Sgroi A., Mai G., Baertschiger R. et al. Improved survival of fulminant liver failure by transplantation of microencapsulated cryopreserved porcine hepatocytes in mice // Cell Transplant. - 2009. - N 18 (1). -P. 101-110.
34. Michalopoulos G.K. Principles of liver regeneration and growth homeostasis // Compr. Physiol. - 2013. -N 1. - P. 485-513.
35. Mizuno S., Nakamura T. Improvement of sepsis by Hepatocyte Growth Factor, an anti-inflammatory regulator: emerging insights and therapeutic potential [Электронный ресурс] // Gastroenterology Research and Practice. - 2012. - N 1. - Режим доступа: www.dx.doi.org/10.1155/2012/909350.
36. Nagata H., Nishitai R., Shirota C., Zhang J.L. et al. Prolonged survival of porcine hepatocytes in cynomolgus monkeys // Gastroenterology. - 2007. - N 132 (1). -P. 321-329.
37. Nguyen T.H., Khakhoulina T., Simmons A., Morel P. et al. A simple and highly effective method for the stable transduction of uncultured porcine hepatocytes using lentiviral vector // Cell Transplant. - 2005. - N 14 (7). -P. 489-496.
38. Oh S.H., Kim K.M., Kim D.Y., Kim Y. et al. Improved outcomes in liver transplantation in children with acute liver failure // J. Pediatr. Gastroenterol. Nutr. - 2014. -N 58 (1). - P. 68-73
39. Pan X., Du W., Yu X., Sheng G. et al. Establishment and characterization of immortalized porcine hepatocytes for the study of hepatocyte xenotransplantation // Transplant. Proc. - 2010. - N 42 (5). - P. 1899-1906
40. Poncelet A.J., Denis D., Gianello P. Cellular xenotransplantation // Curr. Opin. Organ. Transplant. - 2009. -N 14 (2). - P. 168-174.
41. Sengupta S., Sellers L.A., Cindrova T., Skepper J. et al. Cyclooxygenase-2-selective nonsteroidal anti-inflammatory drugs inhibit Hepatocyte Growth Factor/Scatter Factor-induced angiogenesis // Cancer Res. - 2013. -N 63 (23). - P. 8351-8359.
42. Sgroi A., Mai G., Morel P., Baertschiger R.M. et al. Transplantation of encapsulated hepatocytes during acute liver failure improves survival without stimulating native liver regeneration // Cell Transplant. - 2011. -N 20 (11-12). - P. 1791-1803.
43. Shimizu K., Taniyama Y., Sanada F., Azuma J. et al. Hepatocyte growth factor inhibits lipopolysaccha-ride-induced oxidative stress via epithelial growth factor receptor degradation // Arterioscler. Thromb. Vasc. Biol. - 2012. - N 32 (11). - P. 2687-2693.
44. Song S.M., Cho M.S., Oh S.H., Kim K.M. et al. Liver transplantation in a child with acute liver failure resulting from drug rash with eosinophilia and systemic symptoms syndrome // Korean J. Pediatr. - 2013. - N 56 (5). -P. 224-226.
45. Song S.W., Lee S.J., Kim C.Y., Song J.K. et al. Inhibition of tumor growth in a mouse xenograft model by the humanized anti-HGF monoclonal antibody YYB-101 produced in a large-scale CHO cell culture // J. Microbiol. Biotechnol. - 2013. - N 23 (9). - P. 1327-1338.
46. Taki-Eldin A., Zhou L., Xie H.Y., Zheng S.S. Liver regeneration after liver transplantation // Eur. Surg. Res. - 2012. - N 48 (3). - P. 139-153.
47. Vosough M., Omidinia E., Kadivar M., Shokrgozar M.A. et al. Generation of functional hepatocyte-like cells from human pluripotent stem cells in a scalable suspension culture // Stem Cells Dev. - 2013. - N 22 (20). -P. 2693-2705.
48. Xie C., Zheng Y.B., Zhu H.P., Peng L. et al. Human bone marrow mesenchymal stem cells are resistant to HBV infection during differentiation into hepatocytes in vivo and in vitro // Cell Biol. Int. - 2009. - N 33 (4). -P. 493-500.
49. Zhang J., Middleton K.K., Fu F.H. et al. HGF mediates the anti-inflammatory effects of PRP on injured tendons [Электронный ресурс] // PLoS One. - 2013. -N 8 (6). - Режим доступа: www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0067303.
50. Zheng M.H., Lin H.L., Qiu L.X., Cui Y.L. et al. Mixed microencapsulation of rat primary hepatocytes and Sertoli cells improves the metabolic function in a D-galactosamine and lipopolysaccharide-induced rat model of acute liver failure // Cytotherapy. - 2009. -N 11 (3). - P. 326-329.
Review
For citations:
Iskra A.I., Lepekhova S.A. PROSPECT OF USING BIOTECHNOLOGIES FOR CORRECTION OF LIVER FAILURE (Review of literature). Acta Biomedica Scientifica. 2014;(1):112-119. (In Russ.)
Views:
358
.png)
Email this article 
